Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis
Open Access
- 1 March 2001
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (3), 966-968
- https://doi.org/10.1128/aac.45.3.966-968.2001
Abstract
The synergism of voriconazole (VRC) and terbinafine was studied by using 39 genotypically defined clinical Candida albicans isolates that were cross-resistant to fluconazole and VRC and serial isolates that gradually developed azole resistance. Synergy was noticed in 100% (eight of eight) of the strains that were resistant to VRC. Antagonism was not observed.Keywords
This publication has 7 references indexed in Scilit:
- Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosisJournal of Antimicrobial Chemotherapy, 2000
- Nonparametric methods for paired samplesStatistica Neerlandica, 1999
- Comparative in Vitro Activity of Voriconazole and Itraconazole Against Fluconazole-Susceptible and Fluconazole-Resistant Clinical Isolates of Candida Species from SpainEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Multiple Molecular Mechanisms Contribute to a Stepwise Development of Fluconazole Resistance in Clinical Candida albicans StrainsAntimicrobial Agents and Chemotherapy, 1998
- In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azolesAntimicrobial Agents and Chemotherapy, 1997
- Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasisBritish Journal of Dermatology, 1996
- Fluconazole-Resistant Candida albicans After Long-term Suppressive TherapyArchives of Internal Medicine, 1993